Drug Discovery for Neglected Diseases: View of A Public-Private Partnership

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

Volumn , Issue , 2009, Pages 33-43

  Don, Rob ^a   Chatelain, Eric ^a  

^a DND i (Drugs for Neglected Diseases Initiative)   (Switzerland)

Author keywords

Chagas' disease; Drug discovery; Human african trypanosomiasis; Lead optimization; Neglected diseases; Product development partnership; Visceral leishmaniasis

Indexed keywords

EID: 77954064822     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626816.ch3     Document Type: Chapter

References (17)

1. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22, 151-185.
2. Pepin, J., Milord, F., Khonde, A.N., Niyosenga, T., Loko, L., Mpia, B. and De Wals, P. (1995) Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 92-97.
3. Chappuis, F., Udayraj, N., Sietenroth, K., Meussen, A. and Bovier, P.A. (2005) Eflornithine is safer than Melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense Human African trypanosomiasis. Clinical Infectious Diseases, 41, 748-751.
4. Laura-Pires, L., Nitz, N., Vexenat, C., Arganaraz, E.R., D'Souza-Ault, M., Nascimento, R.J. et al. (2001) The treatment of Chagas' disease patients with nitroderivative is unsatisfactory. Revista do Instituto de Medicina Tropical de Sao Paulo, 43, 175-181.
5. Poli, P., Aline de Melo, M., Buschini, A., Mortara, R.A., Northfleet de Albuquerque, C., da Silva, S., Rossi, C. et al. (2002) Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests. Biochemical Pharmacology, 64, 1617-1627.
6. Moran, M.A. (2005) breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Medicine, 2 (9), e309.
7. Croft, L.C. (2005) Public-private partnership: From there to here. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005 (Suppl. 1), S9-S14.
8. Simarro, P.P., Jannin, J. and Cattand, P. (2008) Eliminating human frican trypanosomiasis: where do we stand and what comes next. PLoS Medicine, 5 (2), e55.
9. Barrett, M.P., Boykin, D.W., Brun, R. and Tidwell, R.R. (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. British Journal of Pharmacology, 152, 1155-1171.
10. Croft, S.L., Barrett, M.P. and Urbina, J.A. (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends in Parasitology, 21, 508-512.
11. Murray, H.W., Berman, J.D., Davies, C.R. and Saravia, N.G. (2005) Advances in leishmaniasis. The Lancet, 366, 1561-1577.
12. Alvar, J., Croft, S. and Olliaro, P. (2006) Chemotherapy in the treatment and control of leishmaniasis. Advances in Parasitology, 61, 223-274.
13. Tarleton, R.L., Rethinger, R., Urbina, J.A., Kitron, U. and Gürtler, R.E. (2007) The challenges of Chagas' Disease-Grim outlook or glimmer of hope. PLoS Medicine, 4 (12), e322.
14. Pecoul, B. (2004) New drugs for neglected diseases: From pipeline to patients. PLoS Medicine, 1 (1), e6.
15. Preziosi, P. (2004) Attrition rate R&D of pharmaceutical drugs. Nature Reviews Drug Discovery, 3, 521-526.
16. Woosley, R.L. and Cossman, J. (2007) Drug development and the FDA's critical path initiative. Clinical Pharmacology Revue, 81, 129-133.
17. Curry, S. and Brown, R. (2003) The Target Product Profile as a planning tool in drug discovery research. Business Briefing. Pharmatech 2003, pp. 67-71.